We Give Shareholders a Voice
Levi & Korsinsky announces the filing of a class action lawsuit in the United States District Court for the District of New Jersey on behalf of shareholders who purchased Aerie Pharmaceuticals, Inc. (NASDAQGM: AERI) securities between August 6, 2014 and April 23, 2015.
The complaint alleges that during the Class Period, Aerie Pharmaceuticals made false and misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for Rhopressa. On April 23, 2015, Aerie Pharmaceuticals issued a release announcing that Rhopressa did not meet its “primary efficacy endpoint” in its first Phase 3 registration trial. Upon this news, shares of Aerie Pharmaceuticals fell more than 60 percent to close at $12.87 per share on April 24, 2015. If you suffered a loss in Aerie Pharmaceuticals you have until June 29, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.